- Home
- MYGN vs LAUR Comparison
MYGN vs LAUR Comparison
Compare MYGN & LAUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- LAUR
- Stock Information
- Founded
- MYGN 1991
- LAUR 1989
- Country
- MYGN United States
- LAUR United States
- Employees
- MYGN N/A
- LAUR N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- LAUR Other Consumer Services
- Sector
- MYGN Health Care
- LAUR Real Estate
- Exchange
- MYGN Nasdaq
- LAUR Nasdaq
- Market Cap
- MYGN 2.0B
- LAUR 2.8B
- IPO Year
- MYGN 1995
- LAUR 2017
- Fundamental
- Price
- MYGN $13.36
- LAUR $18.37
- Analyst Decision
- MYGN Hold
- LAUR Buy
- Analyst Count
- MYGN 12
- LAUR 2
- Target Price
- MYGN $23.92
- LAUR $18.50
- AVG Volume (30 Days)
- MYGN 942.4K
- LAUR 632.1K
- Earning Date
- MYGN 11-07-2024
- LAUR 02-20-2025
- Dividend Yield
- MYGN N/A
- LAUR 3.81%
- EPS Growth
- MYGN N/A
- LAUR 137.96
- EPS
- MYGN N/A
- LAUR 1.57
- Revenue
- MYGN $823,600,000.00
- LAUR $1,552,681,000.00
- Revenue This Year
- MYGN $13.82
- LAUR $6.85
- Revenue Next Year
- MYGN $4.59
- LAUR $3.53
- P/E Ratio
- MYGN N/A
- LAUR $11.70
- Revenue Growth
- MYGN 12.15
- LAUR 9.25
- 52 Week Low
- MYGN $12.87
- LAUR $12.45
- 52 Week High
- MYGN $29.30
- LAUR $19.98
- Technical
- Relative Strength Index (RSI)
- MYGN 26.22
- LAUR 45.91
- Support Level
- MYGN $12.87
- LAUR $17.92
- Resistance Level
- MYGN $15.44
- LAUR $19.45
- Average True Range (ATR)
- MYGN 0.84
- LAUR 0.40
- MACD
- MYGN -0.02
- LAUR -0.17
- Stochastic Oscillator
- MYGN 12.37
- LAUR 22.57
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About LAUR Laureate Education Inc.
Laureate Education Inc is an international community of universities. The company provides higher education programs and services to students through an international network of licensed universities and higher education institutions. Its geographical segments include Peru and Mexico.